Oxabispidine compounds for the treatment of cardiac arrhythmias

Details Oxabispidine compounds for the treatment of cardiac arrhythmias Oxabispidine compounds for the treatment of cardiac arrhythmias

2011-04-19

2011-04-19

Habte, Kahsay T (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Chalcogen in the nitrogen containing substituent

C514S230500

Reexamination Certificate

active

07928225

ABSTRACT:
There is provided compounds of formula I, wherein R1, R2, R3, R41to R46, X, Y and Z have meanings given in the description, which compounds are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

REFERENCES:
patent: 3196154 (1965-07-01), Steck et al.
patent: 3503939 (1970-03-01), Williams et al.
patent: 3962449 (1976-06-01), Binnig et al.
patent: 4459301 (1984-07-01), Binnig et al.
patent: 4533713 (1985-08-01), Howells
patent: 4550112 (1985-10-01), Schoen et al.
patent: 4556662 (1985-12-01), Binnig et al.
patent: 5140033 (1992-08-01), Schriewer et al.
patent: 5468858 (1995-11-01), Berlin et al.
patent: 5831099 (1998-11-01), Dave et al.
patent: 6559143 (2003-05-01), Bjore et al.
patent: 6936712 (2005-08-01), Pavey
patent: 7164017 (2007-01-01), Cladingboel et al.
patent: 7169921 (2007-01-01), Cheema et al.
patent: 7217708 (2007-05-01), Barnwell et al.
patent: 7354917 (2008-04-01), Bjore et al.
patent: 7648985 (2010-01-01), Bjore et al.
patent: 2004/0133000 (2004-07-01), Cheema et al.
patent: 2007/0197519 (2007-08-01), Cheema et al.
patent: 306871 (1988-09-01), None
patent: 308843 (1988-09-01), None
patent: 655228 (1995-05-01), None
patent: 1330461 (2002-04-01), None
patent: 1330462 (2002-04-01), None
patent: 1235831 (2005-03-01), None
patent: 1559717 (2005-03-01), None
patent: 1256850 (1971-12-01), None
patent: 8200945 (1988-04-01), None
patent: 5772977 (1982-05-01), None
patent: 6284070 (1994-10-01), None
patent: 6284071 (1994-10-01), None
patent: 2003512352 (2003-04-01), None
patent: 9107405 (1991-05-01), None
patent: 9931100 (1999-06-01), None
patent: 0061569 (2000-10-01), None
patent: 0128992 (2001-04-01), None
patent: 0228863 (2002-04-01), None
patent: 0228864 (2002-04-01), None
patent: 02083688 (2002-10-01), None
patent: 02083690 (2002-10-01), None
patent: 02083691 (2002-10-01), None
patent: 2002083687 (2002-10-01), None
patent: 03101956 (2003-11-01), None
patent: 2004035592 (2004-04-01), None
patent: WO2005/123747 (2005-06-01), None
patent: 2005123748 (2005-12-01), None
Yoshidome et al., “Infrared spectroscopic analyses of transformations of chemical species on the silica highly-reacted with gaseous BF3,” (2003) 19:429-435.
Bogousslavsky et al., “Pure midbrain infarction: clinical syndromes, MRI, and etiologic patterns,” (1994) Neurology 44:2032-2040.
[No Authors Listed] “Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investgators,” New England Journal of Medicine (1989) 321(6): 406-412.
Chapman et al., “Nitrolysis of a Highly Deactivated Amide by Protonitronium. Synthesis and Structure of HNFX(1),” J Org Chem (1999) 64(3):960-965.
Chapman et al., “Difluoramination of Heterocyclic Ketones: Control of Microbasicity,” J Org Chem (1998) 63 (5):1566-1570.
Chen et al., “High-Performance Liquid Chromatographic Determination of SAZ-VII-22, a Novel Antiarrhythmic Agent, in Dog Plasma and Urine,” Anal Sci (1993) 9(3):429-431.
Dave et al., “Facile Preparation of 3,7-Diazabicyclo[3.3.0]octane and 3,7,10-Triheterocyclic [3.3.3]Propellane Ring Systems from 1,5-Diazacyclooctane 3,7-Derivatives,” J Org Chem (1996) 61(25):8897-8903.
Jeyaraman et al., “Chemistry of 3-azabicyclo[3.3.1]nonanes,” Chem Rev (1981) 81(2):149-174.
Garrison et al., “Novel 3,7-diheterabicyclo[3.3.1]nonanes that possess predominant class III antiarrhythmic activity in 1-4 day post infarction dog models: X-ray diffraction analysis of 3-[4-(1H-imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nona ne dihydroperchlorate,” J Med Chem (1996) 39(13):2559-2570.
Lange et al., “Facile Conversion of Primary and Secondary Alcohols to Alkyl Iodides,” Synthetic Communication (1990) 20(10):1473-1479.
Nemec et al., “Pharmacotherapy of atrial fibrillation,” Expert Opinion of Pharmacotherapy (1999) 1(1):81-96.
Nelson et al., “Synthesis of 2,5- and 2,6-bis(bromomethyl)-1,4-diphenylpiperazines and their conversion into 2,5-diphenyl-2,5-diazabicyclo[2.2.2]octane,” J Org Chem (1971) 36(22):3361-3365.
Paroczai et al., “Investigations to characterize a new antiarrhythmic drug bisaramil,” Pharmacol Res (1991) 24 (2):149-162.
Paudler et al., “3,7-Disubstituted octahydro-1,5-diazocines. Their conversion into tetrahydro-1,5-diazocines and to ring-contracted products,” J Org Chem (1967) 32(8):2425-2430.
Paulder et al., “1,5-Bis(p-toluenesulfonyl)-3,7-Dihydroxyoctahydro-1,5-diazocine,” J Org Chem (1966) 31(1):277-281.
Steck et al., “3-Substituted 9-Methyl-3,9-Diazabicyclo[3.3.1]nonanes,” J Org Chem (1963) 28(9):2233-2238.
Stetter et al., “Synthese des 1,3-Diaza-6-oxa-adamantans,” Chem Ber (1963) 96(11):2827-2830.
Villa et al., “3,8-diazabicyclo—[3.2.1]-octane derivatives as analogues of ambasilide, a Class III antiarrhythmic agent,” Eur J. Med Chem (2001) 36(6):495-506.
Wang et al., “Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide,” Circulation (1994) 90 (4):2032-2040.
Chemical Abstracts, vol. 56, (1962), No. 154911, Nikitskya et al., Zh. Obshich 31:3202-3205 (1961).
Chemical Abstracts, vol. 59, (1963) No. 7474h, Cignarelli et al., Gazz. Chim. Ital. 93(4):320-328 (1963).
Chemical Abstracts, vol. 59, (1963) No. 2822c, Cignarelli et al., Gazz. Chim. Ital. 93(4):226-237 (1963).
Chemical Abstracts, vol. 46 (1952) No. 992f, Zu-Yoong Kyi et al., J Chem Soc pp. 1706-1708 (1963).
Chemical Abstracts, vol. 48, (1954) No. 2068d, Barnes et al., J Am Chem Soc 75:975-977 (1953).
Chemical Abstracts, vol. 55, (1961) No. 19010d, Rubstov et al., J Med Pharm Chem 3:441-460 (1961).
Tsukerman et al., “Basicity and Structure of Heterocyclic Alpha, Beta- Unsaturated Ketones,” Zh Obshch Khim (1963) 33(9):3110-3112.
Notice of Allowance dated Nov. 9, 2007 for copending U.S. Appl. No. 11/570,439.
Office Action dated Oct. 2, 2007 received in Copending U.S. Appl. No. 11/612,826.
Notice of Allowance dated Mar. 2, 2005 for copending U.S. Appl. No. 10/474,585.
Notice of Allowance dated Feb. 14, 2006 for copending U.S. Appl. No. 10/474,593.
Office Action dated Mar. 20, 2006 for copending U.S. Appl. No. 10/474,593.
Office Action dated Jun. 23, 2006 for copending U.S. Appl. No. 10/474,593.
Weinges et al., “[Uber den mechanismus der saurekatalysierten Kondensations-reaktionen der Hydroxy-flavane und Hydroxy-flavanole-(3)],” (1963) 96:2870-2878.
Rubtsov et al., “Synthesis and pharmacological investigation of derivatives of 9-methyl-3,9-diazabicyclo-(3,3,1)-nonane,” J Med Pharm Chem (1961) 3(3):441-459.
Kyi et al., “Synethic analgesics and related compounds. Part II. Some derivatives of 3:7-diazabicyclo[3:3:1]nonane (Bispidine),” J. Chem Soc. (1951) 1706-1705.
Nikitskaya et al., “Bicyclic systems based on 2,6-lutidine. V. Bisquaternary salts of—bis(9-methyl-3,9-diazabicyclo [3.3.1]nonan-3-yl)alkanes,” Zh. Obshich. Khim. (1961) 31:3202-3205; Chemical Abstracts, vol. 56 (1962), Abstract No. 15491.
Cignarella et al., “Intramolecular acyl migration in the 3.9-diazabicycla [3.3.1]-nonane series,” Gazz. Chim. Ital., (1963) 93(4):320-328; chemcial abstracts, vol. 59 (1963), Abstract No. 7474.
Cignarella et al., “Investigation on 3,9-diazabicyclo[3.3.1]nonanes. Sterochemistry and analgesic activity of 3,9-diazabicyclo [3.3.1]octane derivatives,” Gazz Chim Ital (1963) 93:226-37; Chemical Abstracts, vol. 59 (1963), Abstract No. 2822.
Notice of Allowance dated Mar. 2, 2009 received in copending U.S. Appl. No. 12/029,483.
Office Action dated Mar. 24, 2010, received in copending U.S. Appl. No. 12/497,792.
U.S. Office Action dated Jan. 7, 2009 cited in copending U.S. Appl

Affiliated with

Also associated with

Rating

Oxabispidine compounds for the treatment of cardiac arrhythmias does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oxabispidine compounds for the treatment of cardiac arrhythmias, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxabispidine compounds for the treatment of cardiac arrhythmias will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2711968